HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc. (OTCQX: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that its common stock began trading on the quality-controlled OTCQX on Friday, June 1, 2012. OTCQX is the highest tier, premier trading platform for OTC companies, and Bio-Path is very pleased to have qualified for the OTCQX given its high standards. The Company also announced that it has retained Roth Capital Partners to serve as the Company’s Designated Advisor for Disclosure (“DAD”) on OTCQX, responsible for providing guidance on OTCQX requirements.
